{"id":"exelon-rivastigmine","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Nausea"},{"rate":"15–25","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"10–15","effect":"Dizziness"},{"rate":"10–15","effect":"Headache"},{"rate":"10–15","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking the breakdown of acetylcholine, a neurotransmitter critical for memory and cognition, rivastigmine increases its availability in the central nervous system. This dual inhibition of both acetylcholinesterase and butyrylcholinesterase distinguishes it from other cholinesterase inhibitors. The increased acetylcholine helps compensate for neuronal loss in Alzheimer's disease and other dementias.","oneSentence":"Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase enzymes, increasing acetylcholine levels in the brain to improve cognitive function in dementia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:04.735Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Mild to moderate Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT07464340","phase":"PHASE1","title":"Rivastigmine Transdermal Patches Bioequivalence and Adhesion Assessment","status":"COMPLETED","sponsor":"Zodiac Produtos Farmaceuticos S.A.","startDate":"2023-05-12","conditions":"Bioequivalence Study in Healthy Subjects","enrollment":68},{"nctId":"NCT07208344","phase":"EARLY_PHASE1","title":"Intravenous Infusion of Umbilical Cord Blood as an Adjunctive Treatment for Alzheimer's Disease","status":"RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-07-31","conditions":"Alzheimer Disease (AD)","enrollment":30},{"nctId":"NCT05564169","phase":"PHASE3","title":"Masitinib in Patients With Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-06","conditions":"Alzheimer Disease","enrollment":600},{"nctId":"NCT04226248","phase":"PHASE3","title":"CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in Parkinson's Disease)","status":"COMPLETED","sponsor":"University of Bristol","startDate":"2020-01-02","conditions":"Parkinson Disease","enrollment":600},{"nctId":"NCT02670161","phase":"PHASE4","title":"Quality Improvement and Practice Based Research in Neurology Using the EMR","status":"ENROLLING_BY_INVITATION","sponsor":"Endeavor Health","startDate":"2016-05","conditions":"Brain Tumors, Epilepsy, Migraine","enrollment":3300},{"nctId":"NCT06382649","phase":"PHASE2","title":"Rivastigmine for Antimuscarinic Delirium","status":"SUSPENDED","sponsor":"Washington University School of Medicine","startDate":"2026-11","conditions":"Anticholinergic Toxicity","enrollment":42},{"nctId":"NCT06399679","phase":"PHASE2","title":"Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-11-04","conditions":"Anticholinergic Toxicity","enrollment":42},{"nctId":"NCT04366518","phase":"EARLY_PHASE1","title":"Toward a Computationally-Informed, Personalized Treatment for Hallucinations","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-07-15","conditions":"Hallucinations, Auditory, Psychosis","enrollment":35},{"nctId":"NCT06828289","phase":"","title":"Rivastigmine Mini-Tablet for Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-02-28","conditions":"Alzheimer's Disease","enrollment":1000},{"nctId":"NCT06702124","phase":"PHASE3","title":"A Phase 3 Study of Rotigotine in Combination with Rivastigmine in Mild to Moderate Alzheimer's Disease","status":"RECRUITING","sponsor":"I.R.C.C.S. Fondazione Santa Lucia","startDate":"2023-12-01","conditions":"Alzheimer Disease","enrollment":348},{"nctId":"NCT06537076","phase":"PHASE2","title":"Safety and Efficacy of AR1005 in Patients with Lewy Body Disease","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2024-01-01","conditions":"Lewy Body Dementia","enrollment":60},{"nctId":"NCT02989402","phase":"PHASE4","title":"A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-31","conditions":"Alzheimer's Disease","enrollment":100},{"nctId":"NCT05768126","phase":"PHASE4","title":"Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2021-09-29","conditions":"Depressive Disorder","enrollment":100},{"nctId":"NCT05883124","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Applications of Transdermal Patches (9.5 mg/24 h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2023-04-17","conditions":"Bioequivalence","enrollment":38},{"nctId":"NCT03840837","phase":"PHASE4","title":"Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-05-02","conditions":"Parkinson Disease, Parkinson Disease Dementia","enrollment":31},{"nctId":"NCT05853341","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)","status":"COMPLETED","sponsor":"Luye Pharma Group Ltd.","startDate":"2023-05-02","conditions":"Healthy","enrollment":48},{"nctId":"NCT03454646","phase":"PHASE4","title":"Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2024-06-01","conditions":"Alzheimer Disease, Cholinesterase Inhibitors","enrollment":1205},{"nctId":"NCT01872598","phase":"PHASE3","title":"Masitinib in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"AB Science","startDate":"2012-01","conditions":"Alzheimer Disease","enrollment":721},{"nctId":"NCT02839642","phase":"PHASE3","title":"Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy","status":"COMPLETED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2016-07-26","conditions":"Progressive Supranuclear Palsy (PSP)","enrollment":106},{"nctId":"NCT04962841","phase":"","title":"Nutraceuticals and Drug Treatment in Frail Older Adults","status":"UNKNOWN","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2020-04-01","conditions":"Frailty","enrollment":485},{"nctId":"NCT04732182","phase":"NA","title":"Telerehabilitation Alzheimer's Disease Feasibility (TADF)","status":"UNKNOWN","sponsor":"Bright Cloud International Corp","startDate":"2022-02-16","conditions":"Alzheimer Disease, Healthy Aging","enrollment":14},{"nctId":"NCT04731311","phase":"NA","title":"Telerehabilitation Alzheimer's Disease Usability (TADU)","status":"COMPLETED","sponsor":"Bright Cloud International Corp","startDate":"2021-07-29","conditions":"Alzheimer Disease, Healthy Aging","enrollment":4},{"nctId":"NCT05321680","phase":"NA","title":"Withdrawal of Antidementia Drugs in Advanced Dementia (WADAD)","status":"COMPLETED","sponsor":"Centro Hospitalar De São João, E.P.E.","startDate":"2021-03-01","conditions":"Dementia","enrollment":16},{"nctId":"NCT03915626","phase":"EARLY_PHASE1","title":"Effect of Heat on Rivastigmine TDS Products","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2019-10-04","conditions":"Bioavailability","enrollment":7},{"nctId":"NCT05102045","phase":"NA","title":"The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Istanbul Medipol University Hospital","startDate":"2016-09-01","conditions":"Alzheimer Disease","enrollment":27},{"nctId":"NCT03565809","phase":"","title":"Quality of the Management of Diabetes in Elderly People With Dementia in France","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2017-05-02","conditions":"Alzheimer Disease","enrollment":87816},{"nctId":"NCT02444637","phase":"PHASE4","title":"Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD","status":"COMPLETED","sponsor":"National Neuroscience Institute","startDate":"2015-04","conditions":"Alzheimer Disease, CVA (Cerebrovascular Accident)","enrollment":100},{"nctId":"NCT03959124","phase":"NA","title":"Deep Brain Stimulation for Alzheimer's Disease","status":"UNKNOWN","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2020-04-06","conditions":"Alzheimer Disease, Dementia, Alzheimer Type, Deep Brain Stimulation","enrollment":30},{"nctId":"NCT01951118","phase":"PHASE4","title":"Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-10","conditions":"Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders","enrollment":121},{"nctId":"NCT04189666","phase":"PHASE1, PHASE2","title":"Rivastigmine Patch Compared to Melatonin Patch in Prevention of Postoperative Delirium","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2019-11-18","conditions":"Delirium","enrollment":180},{"nctId":"NCT01340885","phase":"PHASE4","title":"Cognitive Decline in Non-demented PD","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2011-01","conditions":"Parkinson's Disease","enrollment":9},{"nctId":"NCT03957174","phase":"NA","title":"Noradrenaline, Acetylcholine and Dynamic Learning in Healthy Humans","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-06-01","conditions":"Healthy","enrollment":107},{"nctId":"NCT03659435","phase":"PHASE1","title":"Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-08-22","conditions":"Bioequivalence","enrollment":58},{"nctId":"NCT02703636","phase":"PHASE4","title":"NextStep:Study to Evaluate Safety,Efficacy & Tolerability of Rivastigmine Patch in Mild to Moderate Alzheimer's Patients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-05-09","conditions":"Mild to Moderate Alzheimer's Disease","enrollment":118},{"nctId":"NCT01856738","phase":"PHASE4","title":"Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease","status":"TERMINATED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-11","conditions":"Parkinson's Disease","enrollment":91},{"nctId":"NCT01852110","phase":"PHASE2","title":"Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-10-22","conditions":"Alzheimer's Disease","enrollment":240},{"nctId":"NCT03573050","phase":"PHASE1","title":"Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase","status":"COMPLETED","sponsor":"SocraTec R&D GmbH","startDate":"2018-05-16","conditions":"Bioequivalence","enrollment":36},{"nctId":"NCT02623764","phase":"","title":"EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors","status":"UNKNOWN","sponsor":"Landspitali University Hospital","startDate":"2015-12","conditions":"Alzheimer´s Disease","enrollment":218},{"nctId":"NCT01585272","phase":"PHASE4","title":"Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Alzheimer's Dementia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-08","conditions":"Alzheimer's Dementia","enrollment":121},{"nctId":"NCT00599287","phase":"PHASE3","title":"Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2008-02","conditions":"Delirium","enrollment":80},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":"Dementia, Depression, Schizophrenia","enrollment":407},{"nctId":"NCT01670526","phase":"PHASE3","title":"Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2012-12","conditions":"Traumatic Brain Injury, Cognitive Impairment","enrollment":94},{"nctId":"NCT01380288","phase":"NA","title":"Cognitive Changes in Alzheimer's Disease Patients Associated With or Without White Matter Changes After Rivastigmine","status":"COMPLETED","sponsor":"Dong-A University","startDate":"2011-06","conditions":"Alzheimer's Disease","enrollment":300},{"nctId":"NCT00099242","phase":"PHASE3","title":"Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-11","conditions":"Alzheimer's Disease, Dementia, Alzheimer Type","enrollment":1040},{"nctId":"NCT01677754","phase":"PHASE2","title":"A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-24","conditions":"Alzheimer's Disease","enrollment":542},{"nctId":"NCT02035982","phase":"PHASE3","title":"Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2010-07","conditions":"Alzheimer's Disease, Dementia","enrollment":40},{"nctId":"NCT01519271","phase":"PHASE4","title":"Mild Cognitive Impairment in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2011-12","conditions":"Parkinson's Disease, Mild Cognitive Impairment","enrollment":28},{"nctId":"NCT00731224","phase":"PHASE4","title":"Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-07","conditions":"Alzheimer's Disease","enrollment":380},{"nctId":"NCT00130338","phase":"PHASE3","title":"Rivastigmine Capsules in Patients With Probable Vascular Dementia","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-02","conditions":"Vascular Dementia","enrollment":521},{"nctId":"NCT01602198","phase":"NA","title":"Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients","status":"TERMINATED","sponsor":"The Cleveland Clinic","startDate":"2011-06","conditions":"Mild Cognitive Disorder, Mild Cognitive Impairment","enrollment":1},{"nctId":"NCT01362686","phase":"NA","title":"Comparative Research of Alzheimer's Disease Drugs","status":"TERMINATED","sponsor":"Indiana University","startDate":"2011-04","conditions":"Dementia, Alzheimer's Disease","enrollment":200},{"nctId":"NCT01047579","phase":"PHASE4","title":"A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-04","conditions":"Alzheimer's Disease","enrollment":51},{"nctId":"NCT00219232","phase":"PHASE3","title":"An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Alzheimer's Disease","enrollment":868},{"nctId":"NCT01948791","phase":"PHASE4","title":"16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-08","conditions":"Alzheimer's Disease","enrollment":222},{"nctId":"NCT00669344","phase":"PHASE4","title":"RIVastigmine In Vascular cognitivE Impairment","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"2006-02","conditions":"Cognitive Impairment","enrollment":50},{"nctId":"NCT00223691","phase":"PHASE1","title":"Treatment of Orthostatic Hypotension in Autonomic Failure","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2002-03","conditions":"Autonomic Failure, Orthostatic Hypotension","enrollment":389},{"nctId":"NCT00158210","phase":"PHASE1","title":"Rivastigmine For Methamphetamine Dependent Individuals","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2006-05","conditions":"Substance-Related Disorders","enrollment":18},{"nctId":"NCT01529619","phase":"PHASE4","title":"Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-03","conditions":"Alzheimer's Disease","enrollment":52},{"nctId":"NCT01614886","phase":"PHASE3","title":"Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-07","conditions":"Alzheimer's Disease","enrollment":216},{"nctId":"NCT01487317","phase":"PHASE3","title":"Rivastigmine in the Management of Delirium","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06","conditions":"Delirium","enrollment":23},{"nctId":"NCT01312363","phase":"","title":"Study for the Tolerability of Exelon Patch (Rivastigmine) for Alzheimer's Disease (AD) Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-06","conditions":"Alzheimer's Disease","enrollment":300},{"nctId":"NCT01944436","phase":"","title":"A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease","status":"COMPLETED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2006-09","conditions":"Lewy Body Disease","enrollment":57},{"nctId":"NCT01023425","phase":"NA","title":"Clinical Trial of Donepezil Between the Naive Group and the Switching Group","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-02","conditions":"Alzheimer's Disease, Dementia","enrollment":72},{"nctId":"NCT02063269","phase":"NA","title":"Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2014-02","conditions":"Alzheimer's Disease","enrollment":70},{"nctId":"NCT02413554","phase":"PHASE4","title":"Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.","status":"COMPLETED","sponsor":"Chung-Ang University Hosptial, Chung-Ang University College of Medicine","startDate":"2013-04","conditions":"Delirium","enrollment":62},{"nctId":"NCT01084135","phase":"PHASE1, PHASE2","title":"Rivastigmine Study in Adolescents With Down Syndrome","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Down Syndrome","enrollment":42},{"nctId":"NCT00835159","phase":"PHASE4","title":"Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2008-12","conditions":"Delirium, Postoperative Cognitive Dysfunction","enrollment":30},{"nctId":"NCT01030692","phase":"PHASE1","title":"Rivastigmine and Huperzine A as Treatments for Cocaine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-01","conditions":"Cocaine Dependence, Cocaine Addiction, Cocaine Abuse","enrollment":72},{"nctId":"NCT02187276","phase":"","title":"The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2009-06","conditions":"Alzheimer Disease, Late Onset","enrollment":129},{"nctId":"NCT01399125","phase":"PHASE3","title":"A 24-Week Efficacy, Safety and Tolerability of Rivastigmine Patch Study in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-07","conditions":"Alzheimer's Disease","enrollment":501},{"nctId":"NCT00428389","phase":"PHASE3","title":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":262},{"nctId":"NCT01348282","phase":"PHASE4","title":"Efficacy and Safety of Two Pharmacologic Strategies on Neurocognitive Impairment in HIV Infection. The TRIANT-TE Study","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2011-05","conditions":"Neurocognitive Disturbance, HIV Infection","enrollment":33},{"nctId":"NCT00624663","phase":"NA","title":"A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2009-01","conditions":"Rivastigmine Toxicity","enrollment":15},{"nctId":"NCT00988117","phase":"PHASE4","title":"The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-04","conditions":"Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems","enrollment":15},{"nctId":"NCT00423085","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":859},{"nctId":"NCT00551161","phase":"PHASE4","title":"Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease","status":"COMPLETED","sponsor":"Northwell Health","startDate":"2007-08","conditions":"Alzheimer Disease","enrollment":12},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00291421","phase":"","title":"A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's Disease","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2002-07","conditions":"Alzheimer Disease, Dementia, Nervous System Diseases","enrollment":2360},{"nctId":"NCT00748007","phase":"NA","title":"Efficacy of Rivastigmine in Patients With Down Syndrome","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Down Syndrome","enrollment":14},{"nctId":"NCT01696591","phase":"","title":"The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD","status":"UNKNOWN","sponsor":"Duk Lyul Na","startDate":"2012-03","conditions":"Alzheimer Disease, Dementia, Brain Diseases","enrollment":14},{"nctId":"NCT01696123","phase":"PHASE2","title":"Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine","status":"COMPLETED","sponsor":"Shahid Beheshti University of Medical Sciences","startDate":"2011-01","conditions":"Alzheimer Disease","enrollment":125},{"nctId":"NCT00506415","phase":"PHASE3","title":"Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-06","conditions":"Alzheimer Disease","enrollment":1584},{"nctId":"NCT01073319","phase":"PHASE1","title":"Rivastigmine as a Treatment for Methamphetamine Dependence","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2009-07","conditions":"Methamphetamine Dependence, Substance Abuse, Methamphetamine Abuse","enrollment":17},{"nctId":"NCT00767091","phase":"PHASE3","title":"Study of Rivastigmine to Treat Parkinsonian Apathy Without Dementia","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2009-03","conditions":"Parkinson's Disease, Apathy, no Dementia","enrollment":40},{"nctId":"NCT00766363","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"FORUM Pharmaceuticals Inc","startDate":"2008-10","conditions":"Alzheimer's Disease, Central Nervous System Diseases","enrollment":49},{"nctId":"NCT00561392","phase":"PHASE4","title":"Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-11","conditions":"Alzheimer's Disease","enrollment":208},{"nctId":"NCT01183806","phase":"PHASE3","title":"Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients","status":"COMPLETED","sponsor":"Federal University of Bahia","startDate":"2010-07","conditions":"Alzheimer Disease","enrollment":40},{"nctId":"NCT00881205","phase":"PHASE4","title":"Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-04","conditions":"Multiple Sclerosis, Cognitive Impairment","enrollment":86},{"nctId":"NCT01146067","phase":"PHASE1","title":"Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-01","conditions":"Healthy","enrollment":44},{"nctId":"NCT00623103","phase":"PHASE3","title":"Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Parkinson's Disease Dementia","enrollment":583},{"nctId":"NCT00171795","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-11","conditions":"Traumatic Brain Injury","enrollment":67},{"nctId":"NCT00099216","phase":"PHASE3","title":"Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-08","conditions":"Vascular Dementia","enrollment":708},{"nctId":"NCT00219245","phase":"PHASE4","title":"An Extension Study Evaluating the Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury (TBI) With Persistent Cognitive Deficits","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-11","conditions":"Traumatic Brain Injury With Persistent Cognitive Deficits","enrollment":157},{"nctId":"NCT00234637","phase":"PHASE4","title":"Rivastigmine Monotherapy and Combination Therapy With Memantine in Patients With Moderately Severe Alzheimer's Disease Who Failed to Benefit From Previous Cholinesterase Inhibitor Treatment","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-11","conditions":"Alzheimer's Disease","enrollment":204},{"nctId":"NCT00627848","phase":"NA","title":"Rivastigmine in Mild Alzheimer's Disease, FMRI Study","status":"COMPLETED","sponsor":"Kuopio University Hospital","startDate":"2007-03","conditions":"Alzheimer' Disease","enrollment":20},{"nctId":"NCT00622713","phase":"PHASE4","title":"A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Alzheimer's Disease","enrollment":228},{"nctId":"NCT00549601","phase":"PHASE4","title":"Convenience, Tolerability, and Safety of Change in the Administration of Rivastigmine From Capsules to a Transdermal Patch in Patients With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-09","conditions":"Alzheimer's Disease","enrollment":142},{"nctId":"NCT00704301","phase":"PHASE4","title":"Rivastigmine for Intensive Care Unit (ICU) Delirium","status":"TERMINATED","sponsor":"UMC Utrecht","startDate":"2008-11","conditions":"Delirium","enrollment":104},{"nctId":"NCT00102856","phase":"PHASE4","title":"Neuromodulation and Language Acquisition (Stage Ib)","status":"SUSPENDED","sponsor":"University Hospital Muenster","startDate":"2005-01","conditions":"Healthy","enrollment":60},{"nctId":"NCT01146041","phase":"PHASE1","title":"Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2004-02","conditions":"Healthy","enrollment":44}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"FALL"},{"count":5,"reaction":"MALAISE"},{"count":5,"reaction":"VOMITING"},{"count":4,"reaction":"CONFUSIONAL STATE"},{"count":4,"reaction":"CONVULSION"},{"count":3,"reaction":"AGITATION"},{"count":3,"reaction":"DIZZINESS"},{"count":3,"reaction":"DRUG INTERACTION"},{"count":3,"reaction":"DYSPNOEA"},{"count":3,"reaction":"LOSS OF CONSCIOUSNESS"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Exelon (rivastigmine)","genericName":"Exelon (rivastigmine)","companyName":"Singapore General Hospital","companyId":"singapore-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine inhibits acetylcholinesterase and butyrylcholinesterase enzymes, increasing acetylcholine levels in the brain to improve cognitive function in dementia. Used for Mild to moderate Alzheimer's disease, Mild to moderate Parkinson's disease dementia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}